Curasight Q2 FY26 operating loss narrows to DKK 11.49 million; net loss improves to DKK 11.43 million

Reuters2026/08/27 05:10

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Curasight posted a Q2 operating loss of DKK 11.49 million, narrowing 39.54% year over year.
Loss for the period narrowed 40.51% to DKK 11.43 million; earnings per share improved to DKK -0.24.
Total assets rose to DKK 56.08 million; equity ratio fell 40.5 percentage points to 27.1%.
Directed share issue raised about DKK 20 million, strengthening the financial position.
Topline uTREAT Phase 1 glioblastoma data seen in H1 2027; uTRACE Phase 2 prostate cancer data also expected in H1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curasight A/S published the original content used to generate this news brief via Cision (Ref. ID: 20260826:BIT:2772:0) on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Curasight Q2 FY26 operating loss narrows to DKK 11.49 million; net loss improves to DKK 11.43 million

You may also like

Crypto prices